Wolk, Robert <br/><br/>
Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.  [electronic resource] 

 -  Hypertension (Dallas, Tex. : 1979)  Jun 2009 
 - 1091-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4563 
<br/><br/><label>Standard No.: </label>10.1161/HYPERTENSIONAHA.109.132225  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized<br/>Antihypertensive Agents--administration & dosage<br/>Blood Pressure Monitoring, Ambulatory<br/>Cyclic Nucleotide Phosphodiesterases, Type 5--administration & dosage<br/>Delayed-Action Preparations--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hypertension--diagnosis<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Pharmaceutical Preparations<br/>Phosphodiesterase 5 Inhibitors<br/>Reference Values<br/>Risk Assessment<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult